European Patent Office Confirms Patent Protection for SOT201, SOTIO's Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity

European Patent Office confirmed patent protection for SOT201, supporting IP protection for the next-gen PD-1-targeting immunocytokine. The asset is currently being evaluated in a Phase 1 clinical trial, which may improve investor confidence around development optionality and future commercial defensibility.